Skip to main content

Advertisement

SpringerLink
Log in

Atorvastatin inhibits the inflammatory response caused by anti-M3 peptide IgG in patients with primary Sjögren’s syndrome

  • Research Article
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract

Experimental and clinical investigations have revealed that statins can down-regulate acute and chronic inflammatory processes. Whether statins express anti-inflammatory activities in the salivary glands in patients with primary Sjögren’s syndrome (pSS) is not known. The in vitro and in vivo effect of atorvastatin on rat submandibular gland treated with anti-M3 peptide IgG purified from SS patients was studied. The anti-inflammatory effects of atorvastatin were assessed by measuring the levels of IL-1β, PGE2 and MMP-3 by ELISA. Atorvastatin inhibited the increase in the production of IL-1β, PGE2 and MMP-3 in submandibular glands treated with anti-M3 peptide IgG. A positive correlation between IL-1β production with accumulation of PGE2 and MMP-3 was observed. Rats pre-treated orally with atorvastatin (30 mg kg−1) or vehicle (phosphate-buffered solution) once a day for three consecutive days impaired the increment in the production of IL-1β, PGE2 and MMP-3 in the submandibular gland in the presence of anti-M3 peptide IgG. In conclusion, the anti-inflammatory effects of atorvastatin are dependent upon inhibition of production of a pro-inflammatory cytokine (IL-1β) and pro-inflammatory mediators such as PGE2 and MMP-3. These data suggest that atorvastatin may constitute an anti-inflammatory effect in SS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Bacman S, Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E (1998) Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjögren’s syndrome. Invest Ophthalmol Vis Sci 39:151–156

    PubMed  CAS  Google Scholar 

  • Barsante MM, Roffe E, Yokoro CM, Tafuri WL, Souza DG, Pinho V et al (2005) Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 516:282–289

    Article  PubMed  CAS  Google Scholar 

  • Baturone R, Soto MJ, Márquez M, Macías I, de Oca MM, Medina F, Chozas N, García-Pérez S, Girón-González JA (2009) Health-related quality of life in patients with primary Sjögren’s syndrome: relationship with serum levels of proinflammatory cytokines. Scand J Rheumatol 38:386–389

    Article  PubMed  CAS  Google Scholar 

  • Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J (2003) Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63:12–23

    Article  PubMed  CAS  Google Scholar 

  • Bolstad AI, Eiken HG, Rosenlund B, Alarcón-Riquelme ME, Jonsson R (2003) Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren’s syndrome. Arthritis Rheum 48:174–185

    Article  PubMed  CAS  Google Scholar 

  • Borda E, Sterin-Borda L (2001) Autoantibodies against neonatal heart M1 muscarinic acetylcholine receptor in children with congenital heart block. J Autoimmun 16:143–150

    Article  PubMed  CAS  Google Scholar 

  • Borda E, Passafaro D, Reina S, Sterin-Borda L (2011) Modulation of c-Jun NH2-terminal (JNK) by cholinergic autoantibodies from patients with Sjögren’s syndrome. Pharmacol Pharm 2:256–265

    CAS  Google Scholar 

  • Cao C, Matsumura K, Yamagata K, Watanabe Y (1996) Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1 beta: a possible site of prostaglandin synthesis responsible for fever. Brain Res 733:263–272

    Article  PubMed  CAS  Google Scholar 

  • Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R (1995) Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 76:21A–28A

    Article  PubMed  CAS  Google Scholar 

  • Cunha TM, Verri WA Jr, Silva JS, Poole S, Cunha FQ, Ferreira SH (2005) A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci USA 102:1755–1760

    Article  PubMed  CAS  Google Scholar 

  • Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331

    Article  PubMed  CAS  Google Scholar 

  • Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, Smith C, Hewes WE, Ackerman NR (1990) Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 254:180–187

    PubMed  CAS  Google Scholar 

  • Goin JC, Perez-Leiros C, Borda E, Sterin-Borda L (1997) Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J 10:77–83

    Google Scholar 

  • Gottenberg JE, Busson M, Loiseau P et al (2003) In primary Sjögren’s syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 48:2240–2245

    Article  PubMed  CAS  Google Scholar 

  • Gottenberg JE, Cagnard N, Lucchesi C et al (2006) Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. Proc Natl Acad Sci USA 103:2770–2775

    Article  PubMed  CAS  Google Scholar 

  • Grundy SM (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24–33

    Article  PubMed  CAS  Google Scholar 

  • Heerey A, Barry M, Ryan M, Kelly A (2000) The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 169:176–179

    Article  PubMed  CAS  Google Scholar 

  • Jouzeau JY, Terlain B, Abid A, Nédélec E, Netter P (1997) Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 53:563–582

    Article  PubMed  CAS  Google Scholar 

  • Koh KK (2000) Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47:648–657

    Article  PubMed  CAS  Google Scholar 

  • Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H et al (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524–1530

    PubMed  CAS  Google Scholar 

  • Lowry JR, Thiessen R Jr (1950) Studies of the nutritive impairment of proteins heated with carbohydrates; in vitro digestion studies. Arch Biochem 25:148–156

    PubMed  CAS  Google Scholar 

  • Mandl T, Hammar O, Theander E, Wollmer P, Ohlsson B (2010) Autonomic nervous dysfunction development in patients with primary Sjogren’s syndrome: a follow-up study. Rheumatology (Oxford) 49:1101–1106

    Article  Google Scholar 

  • Nakamura H, Kawakami A, Eguchi K (2006) Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjögren’s syndrome. Transat Res 148:281–288

    Article  CAS  Google Scholar 

  • Ng KP, Isenberg DA (2008) Sjögren’s syndrome: diagnosis and therapeutic challenges in the elderly. Drugs Aging 25:19–33

    Article  PubMed  CAS  Google Scholar 

  • Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S (2002) Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren’s syndrome. Arthritis Rheum 46:2730–2741

    Article  PubMed  CAS  Google Scholar 

  • Pflugfelder SC (2004) Antiinflammatory therapy for dry eye. Am J Ophthalmol 137:337–342

    Article  PubMed  Google Scholar 

  • Rapraeger A, Jalkanen M, Bernfield MJ (1986) Cell surface proteoglycan associates with the cytoskeleton at the basolateral cell surface of mouse mammary epithelial cells. Cell Biol 103:2683–2696

    Article  CAS  Google Scholar 

  • Reina S, Sterin-Borda L, Orman B, Borda E (2004) Autoantibodies against cerebral muscarinic cholinoceptors in Sjögren syndrome: functional and pathological implications. J Neuroimmunol 150:107–115

    Article  PubMed  CAS  Google Scholar 

  • Reina S, Orman B, Anaya JM, Sterin-Borda L, Borda E (2007) Cholinoreceptor autoantibodies in Sjögren syndrome. J Dent Res 86:832–836

    Article  PubMed  CAS  Google Scholar 

  • Reina S, Sterin-Borda L, Passafaro D, Borda E (2010) Muscarinic cholinoceptor activation by pilocarpine triggers apoptosis in human skin fibroblast cells. J Cell Physiol 222:640–647

    PubMed  CAS  Google Scholar 

  • Reina S, Sterin-Borda L, Passafaro D, Borda E (2011a) Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren’s syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E2 (PGE2) from the submandibular glands. Arch Oral Biol 56:413–420

    Article  PubMed  CAS  Google Scholar 

  • Reina S, Sterin-Borda L, Passafaro D, Borda E (2011b) Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren’s syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands. Arch Oral Biol 56:413–420

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg GA (2002) Matrix metalloproteinases in neuroinflammation. Glia 39:279–291

    Article  PubMed  Google Scholar 

  • Rosenson RS (1999) Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1:225–232

    Article  PubMed  CAS  Google Scholar 

  • Sachs D, Cunha FQ, Ferreira SH (2004) Peripheral analgesic blockade of hypernociception: activation of arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway. Proc Natl Acad Sci USA 101:3680–3685

    Article  PubMed  CAS  Google Scholar 

  • Santodomingo-Garzón T, Cunha TM, Verri WA Jr et al (2006) Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol 149:14–22

    Article  PubMed  Google Scholar 

  • Solheim S, Seljeflot I, Arnesen H, Eritsland J, Eikvar L (2001) Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis 157:411–415

    Article  PubMed  CAS  Google Scholar 

  • Steinfeld S, Cogan E, King LS, Agre P, Kiss R, Delporte C (2001) Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjögren’s syndrome patients. Lab Invest 81:143–148

    Article  PubMed  CAS  Google Scholar 

  • Sumida T, Tsuboi H, Iizuka M, Nakamura Y, Matsumoto I (2010) Functional role of M3 muscarinic acetylcholine receptor (M3R) reactive T cells and anti-M3R autoantibodies in patients with Sjögren’s syndrome. Autoimmun Rev 9:615–617

    Article  PubMed  CAS  Google Scholar 

  • Tonussi CR, Ferreira SH (1994) Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur J Pharmacol 251:173–179

    Article  PubMed  CAS  Google Scholar 

  • Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM (1993) Preliminary criteria for the classification of Sjögren’s syndrome. Results from a prospective concerted action supported by the European Community. Arthritis Rheum 36:340–347

    Article  PubMed  CAS  Google Scholar 

  • Waterman SA, Gordon TP, Rischmueller M (2000) Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren’s syndrome. Arthritis Rheum 43:1647–1654

    Article  PubMed  CAS  Google Scholar 

  • Weitz-Schmidt G (2002) Statins as anti-inflammatory agents. Trends Pharmacol Sci 23:482–486

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Mrs. Elvita Vannucchi and Alejandro Thornton for their excellent technical assistance. This work was supported by the National Agency for Science and Technology (PICTs 01647 and 02120) and University of Buenos Aires (UBACYT, O 017 and O 003), Buenos Aires, Argentina.

Conflict of interest

The authors deny any conflicts of interest related to this study.

Author information

Authors and Affiliations

  1. Pharmacology Unit, School of Dentistry, Buenos Aires University, Marcelo T de Alvear 2142-4 “B”-1122AAH Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

    Silvia Reina, Daniela Passafaro, Leonor Sterin-Borda & Enri Borda

  2. Argentine National Research Council (CONICET), Buenos Aires, Argentina

    Silvia Reina, Leonor Sterin-Borda & Enri Borda

Authors
  1. Silvia Reina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela Passafaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leonor Sterin-Borda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Enri Borda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Enri Borda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reina, S., Passafaro, D., Sterin-Borda, L. et al. Atorvastatin inhibits the inflammatory response caused by anti-M3 peptide IgG in patients with primary Sjögren’s syndrome. Inflammopharmacol 20, 267–275 (2012). https://doi.org/10.1007/s10787-012-0132-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-012-0132-x

Keywords

Search

Navigation